News/ News/ Oncology Takeda sets sights on first-line lung cancer market with new Alunbrig data Phil Taylor Alecensa, Alunbrig, Non-small cell lung cancer, Novartis, Oncology, Pfizer, Roche, Takeda, Xalkori 0 Comment Pfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a Share X Takeda sets sights on first-line lung cancer market with new Alunbrig data https://pharmaphorum.com/news/takeda-sets-sights-on-first-line-lung-cancer-market-with-new-alunbrig-data/